Drug Profile
Candesartan cilexetil/nifedipine - Bayer HealthCare Pharmaceuticals
Alternative Names: BAY-98-7106; Candesartan cilexetil/nifedipine GITS; Nifedipine GITS/candesartan cilexetil; Nifedipine/candesartan-cilexetilLatest Information Update: 28 Aug 2019
Price :
$50
*
At a glance
- Originator Bayer HealthCare Pharmaceuticals
- Class Antihypertensives; Benzimidazoles; Dihydropyridines; Heart failure therapies; Ischaemic heart disorder therapies; Small molecules; Tetrazoles
- Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Essential hypertension
Most Recent Events
- 28 Aug 2019 No development reported - Phase-II for Essential hypertension in South Korea, Lithuania, Russia, South Africa, Spain, Ukraine, Argentina, Brazil (PO) (Bayer HealthCare Pharmaceuticals pipeline, August 2019)
- 28 Aug 2019 No development reported - Phase-III for Essential hypertension in USA, United Kingdom, Germany, Belgium, Canada, Poland, Italy (PO) (Bayer HealthCare Pharmaceuticals pipeline, August 2019)
- 29 Jan 2019 Chemical structure information added